Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
FASEB J. 2019 May;33(5):6339-6353. doi: 10.1096/fj.201802069RR. Epub 2019 Feb 15.
Classical cystathionine β-synthase-deficient homocystinuria (HCU) is a life-threatening inborn error of sulfur metabolism. Treatment for pyridoxine-nonresponsive HCU involves lowering homocysteine (Hcy) with a methionine (Met)-restricted diet and betaine supplementation. Betaine treatment efficacy diminishes significantly over time due to impairment of betaine-Hcy -methyltransferase (BHMT) function. Little is known regarding the regulation of BHMT in HCU. Using a betaine-responsive preclinical mouse model of HCU, we observed that this condition induces a 75% repression of BHMT mRNA, protein and enzyme activity, and significant depletion of hepatic betaine levels. BHMT repression was proportional to plasma Hcy levels but was not observed in mouse models of homocystinuria due to either methylenetetrahydrofolate reductase or Met synthase deficiency. Both Met supplementation and chemically induced glutathione depletion exacerbated hepatic BHMT repression in HCU mice but not wild-type (WT) controls. Conversely, cysteine treatment normalized hepatic BHMT expression in HCU mice but had no effect in WT control animals. Taurine treatment induced BHMT expression in HCU mice by 5-fold and restored maximal lowering of Hcy levels during long-term betaine treatment with a concomitant normalization of inflammatory cytokine expression and a significantly improved coagulative phenotype. Collectively, our findings indicate that adjuvantial taurine treatment has the potential to significantly improve clinical outcomes in HCU.-Maclean, K. N., Jiang, H, Phinney, W. N., Keating, A. K., Hurt, K. J., Stabler, S. P. Taurine alleviates repression of betaine-homocysteine -methyltransferase and significantly improves the efficacy of long-term betaine treatment in a mouse model of cystathionine β-synthase-deficient homocystinuria.
经典胱硫醚β-合酶缺乏型高同型半胱氨酸血症(HCU)是一种危及生命的先天性硫代谢紊乱。对于吡哆醇反应性 HCU 的治疗,包括通过限制蛋氨酸(Met)摄入和补充甜菜碱来降低同型半胱氨酸(Hcy)。随着时间的推移,甜菜碱治疗的效果会显著降低,因为甜菜碱-Hcy -甲基转移酶(BHMT)的功能受损。关于 HCU 中 BHMT 的调节,我们知之甚少。在一个对甜菜碱有反应的 HCU 临床前小鼠模型中,我们观察到这种情况导致 BHMT mRNA、蛋白和酶活性降低 75%,肝甜菜碱水平显著耗竭。BHMT 的抑制与血浆 Hcy 水平成正比,但在由于亚甲基四氢叶酸还原酶或 Met 合酶缺乏而导致的同型胱氨酸尿症小鼠模型中并未观察到。Met 补充和化学诱导的谷胱甘肽耗竭加剧了 HCU 小鼠的肝 BHMT 抑制,但对 WT 对照无影响。相反,半胱氨酸处理使 HCU 小鼠的肝 BHMT 表达正常化,但对 WT 对照动物没有影响。牛磺酸处理使 HCU 小鼠的 BHMT 表达增加 5 倍,并在长期甜菜碱治疗中恢复最大程度降低 Hcy 水平,同时使炎症细胞因子表达正常化,并显著改善凝血表型。总的来说,我们的研究结果表明,辅助牛磺酸治疗有可能显著改善 HCU 的临床结局。-麦克莱恩,K. N.,江,H,芬尼,W. N.,基廷,A. K.,赫特,K. J.,斯塔尔布,S. P. 牛磺酸减轻了甜菜碱-Hcy -甲基转移酶的抑制作用,并显著提高了胱硫醚β-合酶缺乏型高同型半胱氨酸血症小鼠模型中长期甜菜碱治疗的疗效。